S. 3080 · 117th Congress
Cancer Drug Parity Act of 2021
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SmithSponsor21 cosponsors · 11 D, 9 R, 1 I
D
Brown
TB
D
Baldwin
JB
R
Boozman
RB
D
Blumenthal
SC
R
Collins
SC
R
Capito
KC
R
Cramer
CH
R
Hyde-Smith
AK
D
Klobuchar
EM
D
Markey
JM
R
Moran
CM
D
Murphy
JM
D
Merkley
RS
R
Scott
RW
R
Wicker
SW
D
Whitehouse
LM
R
Murkowski
DF
D
Feinstein
JR
D
Reed
JT
D
Tester
AK
I
King16 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications.
What it does: CRS summary · Introduced in Senate · Oct 27, 2021
Cancer Drug Parity Act of 2021
This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.
To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Cancer Drug Parity Act of 2021
Latest action (Oct 27, 2021): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Oct 27, 2021
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.